Jupiter Neurosciences, Inc. (JUNS) shareholders
Close on Nov 17, 2026Market cap $1.17MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Christer Rosén | 13,069,155 | 39.50% | 13D (active) | Nov 8, 2024 |
| Marshall Hayward | 4,015,176 | – | 13D (active) | Nov 8, 2024 |
| Claes Wahlestedt | 3,333,816 | 10.90% | 13D (active) | Nov 8, 2024 |
| Shaun Brothers | 2,038,971 | 6.70% | 13D (active) | Nov 8, 2024 |
| Alexander Rosén | 1,789,100 | 5.70% | 13D (active) | Nov 8, 2024 |
| PharmAla Biotech Holdings Inc. | 132,867 | 10.10% | 13G (passive) amendment | Sep 30, 2026 |
| Orca Capital AG | 102,564 | 8.40% | 13G (passive) | Aug 21, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of JUNS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 7,112 | 0.92% | $114.25K | New | 0.00% |
| Virtu Financial LLC | 3,083 | 0.40% | $50.00K | +2,902 | 0.00% |
| Geode Capital Management, LLC | 2,081 | 0.27% | $33.44K | −741 | 0.00% |
| Vanguard Capital Management LLC | 1,707 | 0.22% | $27.40K | −3,092 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,122 | 0.15% | $18.01K | −49 | 0.00% |
| XTX Topco Ltd | 437 | 0.06% | $7.02K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 384 | 0.05% | $6.17K | New | 0.00% |
| Northern Trust Corp | 338 | 0.04% | $5.43K | – | 0.00% |
| StoneX Group Inc. | 275 | 0.04% | $5.68K | New | 0.00% |
| Level Four Advisory Services, LLC | 133 | 0.02% | $2.14K | New | 0.00% |
| Vestor Capital, LLC | 29 | 0.00% | $557.00K | −12,917 | 0.03% |
| MidFirst Bank | 13 | 0.00% | $214 | – | 0.00% |
| Citigroup Inc | 7 | 0.00% | $117 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 0M | 2.2% | 6 / 1 | 4 / 3 | 0M | 0M |
| Q1 2026 | 10 | 0M | 3.3% | 5 / 2 | 1 / 6 | 0M | 0M |
| Q4 2025 | 12 | 0M | 1.1% | 5 / 5 | 1 / 2 | 0M | 0M |
| Q3 2025 | 9 | 0M | 2.4% | 7 / 1 | 1 / 0 | 0M | 0M |
| Q2 2025 | 2 | 0M | 0.1% | 0 / 0 | 2 / 5 | 0M | 0M |
| Q1 2025 | 7 | 0M | 0.7% | 5 / 2 | 0 / 1 | 0M | 0M |
| Q4 2024 | 3 | 0M | 0.0% | 3 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marshall A. Hayward | Chief Scientific Officer, Director | 2,995,077 | 388.93% | Jul 13, 2026 |
| Christer Rosen | CEO and Chairman, Director | 11,078,892 | 1438.67% | Jun 4, 2026 |
| Alison D. Silva | President and COO, Director | 112,777 | 14.64% | Jun 4, 2026 |
| Alexander Gustaf Erik Rosen | Chief Administrative Officer | 617,411 | 80.17% | Jul 13, 2026 |
| Saleem Elmasri | Chief Financial Officer | 66,239 | 8.60% | Jun 4, 2026 |
| Andrew Jon Cutler | Director | – | – | Aug 5, 2026 |
| Nicholas H. Hemmerly | Director | 95,550 | 12.41% | Jul 13, 2026 |
| Julie B. Kampf | Director | 82,875 | 10.76% | Jul 13, 2026 |
| Holger Weis | Director | 96,581 | 12.54% | Jul 13, 2026 |
| Tomas Jan Philipson | Director | – | – | Jul 1, 2026 |
| Allison W. Brady | Director | 21,750 | 2.82% | Jun 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marshall A. Hayward Chief Scientific Officer, Director | Mar 2, 2026 | Option exercise | +225,000 | – | – | 2,995,077 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jul 1, 2025 | Buy | +3,100 | $1.02 | $3.16K | 11,078,892 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jul 1, 2025 | Buy | +500 | $1.01 | $505 | 11,075,792 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jul 1, 2025 | Buy | +250 | $1.03 | $258 | 112,777 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jul 1, 2025 | Buy | +250 | $1.03 | $258 | 112,277 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jul 1, 2025 | Buy | +250 | $1.03 | $258 | 112,527 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 30, 2025 | Buy | +250 | $1.04 | $260 | 111,927 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 30, 2025 | Buy | +250 | $1.03 | $258 | 111,677 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 30, 2025 | Buy | +250 | $1.02 | $255 | 111 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 30, 2025 | Buy | +100 | $1.02 | $102 | 111,177 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 30, 2025 | Buy | +100 | $1.05 | $105 | 112,027 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +1,450 | $1.02 | $1.48K | 11,072,092 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +1,000 | $0.98 | $980 | 11,068,642 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +2,000 | $1.01 | $2.02K | 11,070,642 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +700 | $1.03 | $721 | 11,072,792 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +1,500 | $1.04 | $1.56K | 11,074,292 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 30, 2025 | Buy | +1,000 | $1.05 | $1.05K | 11,075,292 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 27, 2025 | Buy | +250 | $1.05 | $263 | 111,077 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 27, 2025 | Buy | +250 | $1.04 | $260 | 110,827 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 27, 2025 | Buy | +100 | $1.04 | $104 | 110,577 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 27, 2025 | Buy | +250 | $1.00 | $250 | 110,477 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 27, 2025 | Buy | +166 | $1.06 | $176 | 11,067,642 |
| Nicholas H. Hemmerly Director | Jun 2, 2025 | Option exercise | +95,550 | – | – | 95,550 |
| Julie B. Kampf Director | Jun 2, 2025 | Option exercise | +82,875 | – | – | 82,875 |
| Marshall A. Hayward Chief Scientific Officer, Director | Jun 2, 2025 | Option exercise | +399,402 | – | – | 2,770,077 |
| Marshall A. Hayward Chief Scientific Officer, Director | Jun 2, 2025 | Option exercise | +389,793 | – | – | 2,370,675 |
| Alexander Gustaf Erik Rosen Chief Administrative Officer | Jun 2, 2025 | Option exercise | +96,608 | – | – | 617,411 |
| Alexander Gustaf Erik Rosen Chief Administrative Officer | Jun 2, 2025 | Option exercise | +164,553 | – | – | 520,803 |
| Holger Weis Director | Jun 2, 2025 | Option exercise | +85,800 | – | – | 96,581 |
| Saleem Elmasri CFO and Secretary | Jun 2, 2025 | Option exercise | +66,293 | – | – | 66,239 |
| Alison D. Silva Pres + Chief Business Officer, Director | Jun 2, 2025 | Option exercise | +110,227 | – | – | 110,227 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 2, 2025 | Option exercise | +476,070 | – | – | 11,067,476 |
| Christer Rosen CEO and Chairman, Director, 10% owner | Jun 2, 2025 | Option exercise | +497,396 | – | – | 10,591,406 |
| Allison W. Brady Director | Jan 22, 2025 | Option exercise | +21,750 | – | – | 21,750 |
| Holger Weis Director | Jan 22, 2025 | Option exercise | +10,781 | – | – | 10,781 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Jupiter Neurosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 285,557 shares on Aug 24, 2026 over the last 90 days.
See a number that looks wrong?